A Vaccine to Prevent Pancreatic Cancer in High-risk Individuals Was Safe and Elicited Durable Immune Responses
Kathleen Medora / aacr - A Vaccine to Prevent Pancreatic Cancer in High-risk Individuals Was Safe and Elicited Durable Immune Responses PHILADELPHIA – A vaccine targeting common KRAS mutations was safe and stimulated KRAS-specific T-cell responses in 90% of study participants who…
AI Summary: An experimental KRAS-targeting vaccine administered to people at high risk for pancreatic cancer proved safe and generated durable immune responses, suggesting a credible path toward interception of pancreatic ductal adenocarcinoma before it takes hold. Researchers report sustained antibody and/or T-cell activity, supporting further development and larger efficacy trials.
Related Stories
Phase 2 POLAR reports pembrolizumab plus olaparib outcomes in HRD pancreatic cancer / 3 months
Daraxonrasib’s ASCO moment sparks rapid clinical uptake for pancreatic cancer / 19 days
Daraxonrasib improves survival versus chemotherapy in metastatic pancreatic cancer / 6 wks
New drug doubles one-year survival in metastatic pancreatic cancer / 3 months
EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 12 days
Long‑term Botensilimab+Balstilimab data show durable responses in MSS CRC / 18 days
Zanidatamab improves PFS over trastuzumab in HER2 GEA / 6 wks
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Government Policy, Obesity, Medicare Advantage (not listed), Wildlife and look for the RSS link.
StackHealth Time Machine